303 related articles for article (PubMed ID: 16677395)
1. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study.
Vigna-Perez M; Hernández-Castro B; Paredes-Saharopulos O; Portales-Pérez D; Baranda L; Abud-Mendoza C; González-Amaro R
Arthritis Res Ther; 2006; 8(3):R83. PubMed ID: 16677395
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis.
Davies RJ; Sangle SR; Jordan NP; Aslam L; Lewis MJ; Wedgwood R; D'Cruz DP
Lupus; 2013 May; 22(6):574-82. PubMed ID: 23632989
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome.
Melander C; Sallée M; Trolliet P; Candon S; Belenfant X; Daugas E; Rémy P; Zarrouk V; Pillebout E; Jacquot C; Boffa JJ; Karras A; Masse V; Lesavre P; Elie C; Brocheriou I; Knebelmann B; Noël LH; Fakhouri F
Clin J Am Soc Nephrol; 2009 Mar; 4(3):579-87. PubMed ID: 19261822
[TBL] [Abstract][Full Text] [Related]
4. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF
Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
[TBL] [Abstract][Full Text] [Related]
5. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
[TBL] [Abstract][Full Text] [Related]
6. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.
Sfikakis PP; Boletis JN; Lionaki S; Vigklis V; Fragiadaki KG; Iniotaki A; Moutsopoulos HM
Arthritis Rheum; 2005 Feb; 52(2):501-13. PubMed ID: 15693003
[TBL] [Abstract][Full Text] [Related]
7. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study.
Boletis JN; Marinaki S; Skalioti C; Lionaki SS; Iniotaki A; Sfikakis PP
Nephrol Dial Transplant; 2009 Jul; 24(7):2157-60. PubMed ID: 19179411
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report.
Edelbauer M; Jungraithmayr T; Zimmerhackl LB
Pediatr Nephrol; 2005 Jun; 20(6):811-3. PubMed ID: 15772840
[TBL] [Abstract][Full Text] [Related]
9. Lupus nephritis: where are we now?
Lightstone L
Curr Opin Rheumatol; 2010 May; 22(3):252-6. PubMed ID: 20305561
[TBL] [Abstract][Full Text] [Related]
10. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
[TBL] [Abstract][Full Text] [Related]
11. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Baldovino S; Menegatti E; La Grotta R; Modena V
Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review.
Contis A; Vanquaethem H; Truchetet ME; Couzi L; Rigothier C; Richez C; Lazaro E; Duffau P
Clin Rheumatol; 2016 Feb; 35(2):517-22. PubMed ID: 26762196
[TBL] [Abstract][Full Text] [Related]
13. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?
Li EK; Tam LS; Zhu TY; Li M; Kwok CL; Li TK; Leung YY; Wong KC; Szeto CC
Rheumatology (Oxford); 2009 Aug; 48(8):892-8. PubMed ID: 19478041
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in systemic lupus erythematosus and lupus nephritis.
Beckwith H; Lightstone L
Nephron Clin Pract; 2014; 128(3-4):250-4. PubMed ID: 25471633
[TBL] [Abstract][Full Text] [Related]
15. Single-dose rituximab in refractory lupus nephritis.
Kotagiri P; Martin A; Hughes P; Becker G; Nicholls K
Intern Med J; 2016 Aug; 46(8):899-901. PubMed ID: 27242250
[TBL] [Abstract][Full Text] [Related]
16. Altered expression of signalling lymphocyte activation molecule receptors in T-cells from lupus nephritis patients-a potential biomarker of disease activity.
Stratigou V; Doyle AF; Carlucci F; Stephens L; Foschi V; Castelli M; McKenna N; Cook HT; Lightstone L; Cairns TD; Pickering MC; Botto M
Rheumatology (Oxford); 2017 Jul; 56(7):1206-1216. PubMed ID: 28387859
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis.
Arce-Salinas CA; Rodríguez-García F; Gómez-Vargas JI
Rheumatol Int; 2012 May; 32(5):1245-9. PubMed ID: 21258801
[TBL] [Abstract][Full Text] [Related]
18. Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: progress to date.
Marks SD; Tullus K
Paediatr Drugs; 2007; 9(6):371-8. PubMed ID: 18052407
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts.
Díaz-Lagares C; Croca S; Sangle S; Vital EM; Catapano F; Martínez-Berriotxoa A; García-Hernández F; Callejas-Rubio JL; Rascón J; D'Cruz D; Jayne D; Ruiz-Irastorza G; Emery P; Isenberg D; Ramos-Casals M; Khamashta MA;
Autoimmun Rev; 2012 Mar; 11(5):357-64. PubMed ID: 22032879
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis.
Sfikakis PP; Souliotis VL; Fragiadaki KG; Moutsopoulos HM; Boletis JN; Theofilopoulos AN
Clin Immunol; 2007 Apr; 123(1):66-73. PubMed ID: 17275413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
